GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

APT-101   Click here for help

GtoPdb Ligand ID: 14335

Synonyms: APT101 | compound 423 [WO2017100558A1] | compound 52 [PMID: 35594649]
Compound class: Synthetic organic
Comment: APT-101 (APIE Therapeutics) is an orally bioavailable small molecule that acts as an apelin receptor (APLNR; APJ) agonist [2]. It activates the apelin/apelin receptor pathway to trigger the repair of pulmonary vascular endothelial cell breakdown that drives damage in fibrotic and sclerotic lung diseases [3,5-8].
We obtained the IUPAC descriptor for the molecule from the FDA Orphan Drug register. This chemical structure was first claimed in a patent series from RTI International [4], and is a structure match for compound 52 in [2].
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 11
Topological polar surface area 85.24
Molecular weight 542.54
XLogP 4.32
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES C1CCC(C1)N2C(=CC(=N2)C(=O)N[C@@H](CCN3CCCC(C3)(F)F)CC(=O)O)C4=C(C=CC=C4)C(F)(F)F
Isomeric SMILES C1(CCCC1)N2N=C(C=C2C3=C(C=CC=C3)C(F)(F)F)C(=O)N[C@H](CC(=O)O)CCN4CC(CCC4)(F)F
InChI InChI=1S/C26H31F5N4O3/c27-25(28)11-5-12-34(16-25)13-10-17(14-23(36)37)32-24(38)21-15-22(35(33-21)18-6-1-2-7-18)19-8-3-4-9-20(19)26(29,30)31/h3-4,8-9,15,17-18H,1-2,5-7,10-14,16H2,(H,32,38)(H,36,37)/t17-/m0/s1
InChI Key HSTYVOXQTWCRDM-KRWDZBQOSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
References
1. FDA. 
Search Orphan Drug Designations and Approvals.
Accessed on 22/01/2026. Modified on 22/01/2026. fda.gov, www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=865821
2. Narayanan S, Dai D, Vyas Devambatla RK, Albert V, Bruneau-Latour N, Vasukuttan V, Ciblat S, Rehder K, Runyon SP, Maitra R. (2022)
Synthesis and characterization of an orally bioavailable small molecule agonist of the apelin receptor.
Bioorg Med Chem, 66: 116789. [PMID:35594649]
3. Niemczyk A, Waśkiel-Burnat A, Zaremba M, Czuwara J, Rudnicka L. (2023)
The profile of adipokines associated with fibrosis and impaired microcirculation in systemic sclerosis.
Adv Med Sci, 68 (2): 298-305. [PMID:37696138]
4. Runyon SP, Maitra R, Narayanan S, Thomas JB, Rehder KSm Olepu S. (2017)
Improved apelin receptor (apj) agonists and uses thereof.
Patent number: WO2017100558A1. Assignee: RTI International Inc. Priority date: 09/12/2016. Publication date: 15/06/2017.
5. Selman M, Pardo A. (2006)
Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers.
Proc Am Thorac Soc, 3 (4): 364-72. [PMID:16738202]
6. Shi N, Wang Y, Xia Z, Zhang J, Jia S, Jiao Y, Wang C, Wang X, Zhao J, Zhang J et al.. (2024)
The regulatory role of the apelin/APJ axis in scarring: Identification of upstream and downstream mechanisms.
Biochim Biophys Acta Mol Basis Dis, 1870 (4): 167125. [PMID:38508477]
7. Wang H, Cong L, Yin X, Zhang N, Zhu M, Sun T, Fan J, Xue F, Fan X, Gong Y. (2022)
The Apelin-APJ axis alleviates LPS-induced pulmonary fibrosis and endothelial mesenchymal transformation in mice by promoting Angiotensin-Converting Enzyme 2.
Cell Signal, 98: 110418. [PMID:35882286]
8. Zielinski M, Chwalba A, Jastrzebski D, Ziora D. (2023)
Adipokines in interstitial lung diseases.
Respir Physiol Neurobiol, 315: 104109. [PMID:37393966]